50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
NASDAQ:MRTX

Mirati Therapeutics - MRTX Stock Forecast, Price & News

$67.24
-0.94 (-1.38%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$67.18
$70.72
50-Day Range
$62.16
$86.70
52-Week Range
$32.96
$195.99
Volume
887,458 shs
Average Volume
1.05 million shs
Market Capitalization
$3.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$116.50

Mirati Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
70.7% Upside
$114.77 Price Target
Short Interest
Bearish
13.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
0.59mentions of Mirati Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$854,900 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($14.14) to ($12.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

381st out of 1,069 stocks

Pharmaceutical Preparations Industry

165th out of 533 stocks

MRTX stock logo

About Mirati Therapeutics (NASDAQ:MRTX) Stock

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Stock News Headlines

What 4 Analyst Ratings Have To Say About Mirati Therapeutics
4 Analysts Have This to Say About Mirati Therapeutics
Piper Sandler Begins Coverage on Mirati Therapeutics (NASDAQ:MRTX)
Mirati Therapeutics (NASDAQ:MRTX) Now Covered by Jonestrading
Amgen’s new cancer drug faces questions about competition
Did Mirati Therapeutics Just Leapfrog Amgen?
Mirati Therapeutics Falls 34%
See More Headlines
Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Company Calendar

Last Earnings
8/03/2022
Today
9/26/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
413
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$114.77
High Stock Price Forecast
$188.00
Low Stock Price Forecast
$80.00
Forecasted Upside/Downside
+73.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-581,780,000.00
Net Margins
-824.57%
Pretax Margin
-820.34%

Debt

Sales & Book Value

Annual Sales
$72.09 million
Book Value
$25.24 per share

Miscellaneous

Free Float
53,600,000
Market Cap
$3.73 billion
Optionable
Optionable
Beta
0.91

Key Executives

  • Mr. David D. Meek (Age 59)
    CEO & Director
    Comp: $974.53k
  • Dr. Charles M. Baum M.D.Dr. Charles M. Baum M.D. (Age 64)
    Ph.D., Founder, Pres, Head of R&D and Director
    Comp: $1.11M
  • Dr. James G. Christensen Ph.D. (Age 54)
    Chief Scientific Officer
    Comp: $784.42k
  • Mr. Benjamin J. Hickey M.B.A.Mr. Benjamin J. Hickey M.B.A. (Age 47)
    Chief Commercial Officer
    Comp: $769.03k
  • Ms. Laurie D. Stelzer (Age 54)
    Chief Financial Officer
  • Ms. Reena R. Desai
    Chief Legal Officer & Corp. Sec.
  • Mr. Michael E. Paolucci (Age 62)
    Chief People Officer
  • Dr. Kelly Covello Ph.D.
    VP & Head of Medical Affairs
  • Mr. Ryan Asay
    VP & Head of Corp. Affairs













MRTX Stock - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRTX shares.
View MRTX analyst ratings
or view top-rated stocks.

What is Mirati Therapeutics' stock price forecast for 2022?

11 Wall Street analysts have issued 12 month price objectives for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $80.00 to $188.00. On average, they anticipate the company's stock price to reach $114.77 in the next twelve months. This suggests a possible upside of 69.3% from the stock's current price.
View analysts price targets for MRTX
or view top-rated stocks among Wall Street analysts.

How have MRTX shares performed in 2022?

Mirati Therapeutics' stock was trading at $146.69 at the beginning of the year. Since then, MRTX shares have decreased by 53.8% and is now trading at $67.79.
View the best growth stocks for 2022 here
.

When is Mirati Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our MRTX earnings forecast
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its quarterly earnings data on Wednesday, August, 3rd. The biotechnology company reported ($3.18) EPS for the quarter, beating analysts' consensus estimates of ($3.53) by $0.35. The biotechnology company had revenue of $5.36 million for the quarter, compared to analysts' expectations of $2.20 million. Mirati Therapeutics had a negative trailing twelve-month return on equity of 53.24% and a negative net margin of 824.57%.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (4.41%), FMR LLC (3.62%), State Street Corp (3.38%), Franklin Resources Inc. (2.63%), Artal Group S.A. (1.98%) and Price T Rowe Associates Inc. MD (1.89%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, Henry J Fuchs, Isan Chen, Jamie Christensen, Julie M Cherrington, Ltd Braslyn, Maria E Martinez, Michael G Grey and Vickie S Reed.
View institutional ownership trends
.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $67.79.

How much money does Mirati Therapeutics make?

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $3.76 billion and generates $72.09 million in revenue each year. The biotechnology company earns $-581,780,000.00 in net income (profit) each year or ($11.85) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

The company employs 413 workers across the globe.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.

This page (NASDAQ:MRTX) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.